Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan...
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -4.95 | -31.589023612 | 15.67 | 15.69 | 10.56 | 374138 | 12.34827882 | CS |
| 4 | -3.63 | -25.2961672474 | 14.35 | 16.11 | 10.56 | 267919 | 14.10542215 | CS |
| 12 | -3.01 | -21.9227967953 | 13.73 | 16.11 | 10.56 | 264458 | 14.03886343 | CS |
| 26 | -0.87 | -7.50647109577 | 11.59 | 16.11 | 8.41 | 267183 | 12.97094973 | CS |
| 52 | 5.32 | 98.5185185185 | 5.4 | 20.9 | 5.17 | 314019 | 12.90551909 | CS |
| 156 | -8.66 | -44.6852425181 | 19.38 | 20.9 | 2.7 | 412613 | 9.49330375 | CS |
| 260 | -17.68 | -62.2535211268 | 28.4 | 55.36 | 2.7 | 339168 | 16.60033315 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
